Bristol-Myers Squibb Company (BMY)

NYQ – Real vaqt narxi. Valyuta: USD

56.45

+0.78 (1.40%)

Yopilishda: May 12, 2026, 4:00 PM EDT

56.21

-0.24 (-0.43%)

Bozor oldidan: May 13, 2026, 4:01 AM EDT

10.05.2026

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

Bristol Myers Squibb NYSE: BMY used its 2026 annual meeting of shareholders to highlight progress in its growth portfolio, pipeline development, balance sheet management and cost-saving initiatives, while shareholders approved all management proposals and rejected a proposal to require an independent board chair.

08.05.2026

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.

07.05.2026

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

06.05.2026

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026.

05.05.2026

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

04.05.2026

Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™.

Videolar

06.02.2026

Positive

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

21.01.2026

Neutral

Final Trade: BMY, IGV, SOXX, GEN, AMZN

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
BMY	Cantor Fitzgerald	Neutral	undefined >> $55	April 22nd 2025
BMY	Piper Sandler	Overweight	undefined >> undefined	April 22nd 2025
BMY	Jefferies	Buy	undefined >> $70	December 16th 2024

Press-relizlar

08.05.2026

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults.

Bristol-Myers Squibb Company (BMY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bristol-Myers Squibb Company (BMY)

Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026

Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know